Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)"

Emmanuel A Tsochatzis¹, Ankur Srivastava², William Rosenberg¹

Affiliations

¹ UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK; Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK. Electronic address: w.rosenberg@ucl.ac.uk.
² UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK; Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK.

PMID: 32981752
DOI: 10.1016/j.jhep.2020.09.007

Comment

Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)"

Emmanuel A Tsochatzis et al. J Hepatol. 2021 Jan.

. 2021 Jan;74(1):248-249.

doi: 10.1016/j.jhep.2020.09.007. Epub 2020 Sep 25.

Authors

Emmanuel A Tsochatzis¹, Ankur Srivastava², William Rosenberg¹

Affiliations

¹ UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK; Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK. Electronic address: w.rosenberg@ucl.ac.uk.
² UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Rowland Hill Street, London NW3 2PF, UK; Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, Pond Street, London NW3 2QG, UK.

PMID: 32981752
DOI: 10.1016/j.jhep.2020.09.007

No abstract available

Keywords: Cirrhosis; NAFLD; Non-invasive fibrosis assessment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest WR is an inventor of the ELF test but receives no related royalties. WR and AS have received speakers' fees from Siemens Healthineers. ET declares no competing interests. Please refer to the accompanying ICMJE disclosure forms for further details.

Comment on

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.
Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, Suri D, Thorburn D, Sennett K, Morgan S, Tsochatzis EA, Rosenberg W. Srivastava A, et al. J Hepatol. 2019 Aug;71(2):371-378. doi: 10.1016/j.jhep.2019.03.033. Epub 2019 Apr 6. J Hepatol. 2019. PMID: 30965069
FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
Wu Y, Kumar R, Huang J, Wang M, Zhu Y, Lin S. Wu Y, et al. J Hepatol. 2021 Jan;74(1):247-248. doi: 10.1016/j.jhep.2020.06.040. Epub 2020 Sep 29. J Hepatol. 2021. PMID: 32994079 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)"

Affiliations

Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)"

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical